Discospondylitis describes the infection of an intervertebral disc and its adjacent cartilaginous end plates and vertebral bodies.
It is commonly bacterial or fungal in origin.
The disease can be challenging to diagnose as signs are variable and sometimes vague.
For the research, neurology specialists retrospectively examined cases which presented at multiple referral sites that have furthered the understanding, clinical and imaging features of discospondylitis.
To date MRI has been the imaging modality of choice, with consistent CT imaging features of discospondylitis in dogs and cats not previously reported in detail.
However with the increased availability of CT in clinical practice, the research set out to examine CT features that could support a diagnosis of discospondylitis.
Discospondylitis in cats is uncommon, and very little research had been undertaken in this area. This research group therefore reported clinical presentation and imaging data about a population of cats, to support the future diagnosis of these cases.
During the three studies*, the researchers found that:
The studies
Vétoquinol has released the results of a survey of 1000 dog owners, which looked into their attitudes towards long-term medication for their pet1.
Owners were asked to rate how important various factors were to them when it came to giving medicine long term to their dog. They were also asked to consider what they felt was most important to their vet when it came to choosing a medicine.
Vétoquinol says the fact that dog owners rate the effectiveness of a medication much more highly than the cost means there is very little reason to compromise on treatment based on a presumption of what clients will want to pay. These findings are also largely very positive in that they suggest that dog owners believe that in many areas vets are making decisions based on criteria that are important to owners. The area where there is the greatest mismatch is over the risk of side effects of medication.
Pet owners think that vets may take the risk of side effects from long-term medications less seriously than the owners themselves might prefer. It suggests that the risk of potential harm, no matter how small the risk of actual harm is, may be more unacceptable to the dog owner than vets and nurses might otherwise presume. When prescribing long-term medication there is a need to talk about the risks associated with medication more openly and to take the client's attitudes to risk into consideration.
1. A survey of 1048 dog owners, carried out by petbuzz, on behalf of Vétoquinol, March 2011
The College says the speed and accuracy of scans produced by the new scanner will revolutionise the treatment of animals at the Queen Mother Hospital for Animals (QMHA). It also reduces the need for animals to be anaesthetised before being scanned, with most patients now only requiring partial sedation.
The new scanner has been named the 'Otter Scanner' after a patient of the RVC whose owner was made a significant donation towards the RVC's charity, the Animal Care Trust, which funded the new machine.
Professor Dan Chan, Professor of Emergency and Critical Care Medicine and Medical Director of the QMHA at the RVC, said: "It is very uncommon that such an incredible leap in the care of animals can be achieved with a single innovation.
"Because of the vast improvement in speed and quality of the images produced by the ‘Otter Scanner’ our specialists are now able to obtain much more detailed images of various diseases affecting our patients so that the best possible treatment can be planned.
"At the RVC, one of our most important missions is to always improve the welfare and care of animals and this latest innovation is just another example of that commitment. We are forever grateful to all our supporters who have made this possible."
The procedure was performed in Canada through an international collaboration between partners from Germany, Canada and the UK, who say that this was a case where the placement of the tumour made it impossible to operate without severely impacting the dog’s quality of life. The most suitable treatment was a total excision of the growth and reconstruction with an implant.
The implant was designed with medical CAD tools by German company, Voxelmed, using 3D imaging from the affected area. The dog's veterinary surgeon, Julius Liptak, contributed to the design to ensure it met specifications and allowing him to plan the procedure in advance.
UK company Renishaw then additively manufactured the patient specific implant (PSI) at the Additive Design In Surgical Solutions (ADEISS) Centre in London, Ontario, Canada.
Ed Littlewood, Marketing Manager at Renishaw’s Medical and Dental Products Division said: "Without the advancements in additive manufacturing technology, this dog would not have had such a long and happy future ahead of him.
"Prior to this case, many veterinary surgeons were unaware that the technology was available. Similar procedures are now being planned in Germany and further research is underway to see how animals can benefit from additively manufactured PSIs.
Jan Klasen, veterinary surgeon, 3D designer and CEO of Voxelmed said: "Without AM technology, it would have been almost impossible to reconstruct the dog’s maxilla after tumour removal, because the area was extremely complex in geometry. The implant had to have a similar shape and functionality as the dog’s existing bone structure.
"Using additive manufacturing to maintain the original shape and function of the oral and nasal cavity ensures a high quality of life for the dog, just as a naturally shaped skull and maxilla helps the dog to breathe and eat easily."
To read the full case study, visit http://www.renishaw.com/en/additive-manufacturing-in-veterinary-surgery-saving-a-well-loved-member-of-the-family--42950.
VetSurgeon is sad to report that Sam Duff, a much loved figure in the profession, died last weekend.
Sam qualified from Edinburgh in 1970, and was a partner in mixed practice in Fife until 2002. More recently, he was a director of Equitique Ltd, an equine reproduction referral practice.
Sam was an active member of BVA Council, and its Member Services Group. He served on SPVS Council from 1993-2002, and was re-elected in 2003. He had recently been elected as Secretary of the Scottish branch of the BVA.
A memorial service will be held at 2.30pm on Thursday 9th July in Younger Hall, St Andrews.
Axiom Veterinary Laboratories has launched SLIT - sublingual immunotherapy treatment - for allergies in cats, dogs and horses.
According to the company, sublingual immunotherapy has been shown to be safe and effective in humans for over 20 years and a recent study has shown it to be a beneficial alternative way of administering immunotherapy to cats, dogs and horses, proving particularly effective in treating animals that failed to respond to allergy shots.
Patients can convert from shots to drops with an initial treatment kit.
Martyn Carpenter, Director of Axiom Laboratories Ltd, said: "Each ACTT Allergy Drop prescription is a custom formulation containing the specific allergens that are causing the pet's discomfort. Allergy drops are prepared in a glycerin solution to provide antigen stability, and have a slightly sweet taste, which assists in palatability and ease of administration. This method greatly reduces irritation and the likelihood of anaphylactic shock and can be administered easily at home by the client, freeing up consult slots and removing the stress which accompanies a visit to the surgery for many pets. This can be a particularly suitable alternative for those clients on a restricted budget, for whom on-going consult and injecting fees can be prohibitive to compliance with immunotherapy treatment. "
For more information, contact Axiom's Diagnostic Support Team on 01626 355655
The study, titled “Development and progression of proteinuria in dogs treated with masitinib for neoplasia: 28 cases (2010 – 2019)”, also suggests that a urine protein: creatinine greater than 0.5 should prompt reassessment within one week.
For the study, the clinical records of 38 dogs referred to a single university teaching hospital between 2010 and 2019 for treatment of neoplasia with masitinib were retrospectively evaluated.
Data was collected at masitinib initiation and at various timepoints following the start of treatment.
Data gathered included the masitinib dose given and any changes to medication administration or dosing since the previous visit, presence of gross disease and the results of haematology and biochemistry profiles, urinalysis and urine cultures.
Urinalysis results were only included if they were performed at a reference laboratory.
At each timepoint, the urine was classified as non-proteinuric (UP:C ≤0.5) or proteinurinc (UP:C >0.5). Proteinuria was then categorised as likely pre-renal, post-renal, physiological renal or pathological renal.
Dogs were grouped based on the presence or absence of proteinuria at baseline. Non-proteinuric dogs were further divided, based on whether proteinuria developed following treatment during the study.
Of the 28 dogs in the study, five were being treated for epitheliotropic lymphoma, one for vulval lymphoma, one for malignant melanoma and 21 for mast cell tumours.
Twenty-two (79%) dogs were non-proteinuric and six were proteinuric at baseline.
Of the dogs that were non-proteinuric at baseline, four (18.2%) developed proteinuria within one month of treatment initiation. Median time to first detection of proteinuria was 14.5 days (range: 13 to 31).
Of the dogs with pre-treatment proteinuria (n=6), masitinib treatment was discontinued due to lack of efficacy in three dogs, and three were euthanased during treatment, two for disease progression and one for an unknown reason.
Dr Margaux Kuijlaars, corresponding author for the paper, said: “Patients developing proteinuria should be investigated to exclude non-renal causes. This should allow for more informed recommendations on the monitoring and management of proteinuria and further masitinib treatment in these patients to be made. Masitinib treatment can be considered in patients with pre-treatment proteinuria and does not inevitably cause worsening of proteinuria.
“The findings of this study add to the evidence base for the use of masitinib in treating neoplasia in small animal patients. The use of masitinib in dogs in this study was off-licence as C-KIT MCT expression was not determined, and many dogs were treated for other tumours.”
Nicola Di Girolamo, Editor of JSAP, said: “Little is known about which dogs are predisposed to becoming proteinuric following treatment with masitinib for neoplasia. Due to the small number of dogs in this study that developed proteinuria, conclusions about predisposing factors cannot be definitely drawn.
"The findings of this study add to the evidence base and demonstrate the need for larger, prospective trials including a control population and longer period of follow-up.”
The full article can be found in the August issue of the Journal of Small Animal Practice and can be read online here: https://www.onlinelibrary.wiley.com/doi/10.1111/jsap.13305. It is open access and can be freely accessed by anyone.
Reference
Miss Herdman faced three charges.
The first was that she indicated to a friend that she would supply diazepam and/or tramadol for use by their husband.
The second was that she supplied diazepam and/or tramadol and/or gabapentin.
The third was that she gave advice on the dosages of diazepam and/or tramadol and/or gabapentin.
Miss Herdman was not present at the hearing and was unrepresented, but the Committee determined that it was appropriate to proceed in her absence as she had been notified, was aware that the hearing was taking place and her absence was voluntary.
However, Miss Herdman had been in contact to indicate her pleas to the charges.
She admitted the intention to supply diazepam and/or tramadol and that she had provided advice on the dosages.
She also admitted that she had supplied diazepam but strongly denied that she had supplied tramadol and/or gabapentin.
Taking all the evidence into account (including messages sent by Miss Herdman and her admissions), the Committee found proven the charges in relation to the intent to supply and the advice on dosages.
The Committee also found proven the charge in relation to the supply of diazepam, but found not proved the charge relating to the supply of tramadol and gabapentin for several reasons, including the fact that the messages sent by Miss Herdman did not point unequivocally to her actually suppling each of the drugs to which she referred.
There was no suggestion that the diazepam was stolen from her place of work.
The Committee found that Miss Herdman’s actions had breached paragraphs 1.5 and 6.5 of the Code of Professional Conduct for Veterinary Nurses.
The committee judged that there were a number of aggravating features of Miss Herdman’s conduct, including that she was not qualified or authorised to prescribe medication to animals, let alone to human beings and that providing a controlled drug to a person who was already taking various painkilling medications was reckless.
The Committee also felt that a reasonable and informed member of the public would be very concerned to learn that a veterinary nurse had supplied a controlled drug to a friend for their personal use.
Regarding the sanction for Miss Herdman, Paul Morris, chairing the Veterinary Nursing Disciplinary Committee and speaking on its behalf, said: “Drawing all the material together, and considering the matter as a whole, the Committee had to impose a proportionate sanction for an isolated incident of serious professional misconduct which arose out of a misguided attempt to help a friend.
"The conduct in question was entirely out of keeping with Miss Herdman’s usual practice and there is no real risk that it will be repeated.
"However, this case was much too serious to take no further action and no useful purpose would be served by postponing a sanction.
“The Committee considered that a warning or reprimand would not be sufficient to satisfy the public interest as veterinary nurses are trusted by the public to deal with medication responsibly and failure to do constitutes a severe breach of trust.
“The Committee therefore considered a period of suspension sufficient to meet the public interest in maintaining the reputation of the profession and declaring and upholding proper standards of conduct for members of the profession.
“The Committee also considered whether a removal order would be appropriate but concluded it would be disproportionate and that such a step would remove from the profession an experienced, competent and valuable veterinary nurse for no discernible benefit.
“It was decided that Miss Herdman’s registration be suspended for a period of three months – a period which is sufficient to mark the gravity of the misconduct while taking into account the circumstances in which it arose.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings/
Budding veterinary impresario Noel Fitzpatrick has announced the dates for the inaugural VET Festival, an outdoor summer event for the profession which will combine world-class CPD with family entertainment and an evening rock concert headlined by Mike Rutherford of Genesis fame.
The VET Festival, sponsored by NVSL and Natural Instinct, will take place in the grounds of the University of Surrey on Saturday 5th and Sunday 6th September 2015.
In a complete departure from the way CPD is usually delivered, lectures will take place in a 1000-seat main theatre marquee in the middle of the university campus, surrounded by smaller breakout tents, exhibitors, family entertainment and 'street food'.
Noel said: "The simple goal of The VET Festival is to provide education which is both cutting-edge and relevant to the day-to-day clinical work of vets, vet nurses and veterinary professionals in companion animal practice. But we also seek to make education fun - like going to a movie - something you can treasure, enjoy and then readily employ in clinical practice.
"There are four lecture strands: orthopaedics, oncology and soft tissue surgery, neurology, and veterinary nursing. Ten education themes will be delivered by world-class lecturers with significant experience in clinical veterinary practice. We will present this education on an innovative platform combining a fun festival atmosphere with dynamic delivery. We aim to provide real value for money, with tickets priced very affordably for a packed educational program which can also form part of the 35 CPD points needed throughout the year."
In addition to Noel himself, speakers at the event (pictured below), include: Will Eward (Assistant Professor of Orthopaedic Surgery Duke University), Nick Bacon (Head of Surgical Oncology, Fitzpatrick Referrals), Julia Tomlinson (Diplomate, American College of Veterinary Sports Medicine and Rehabilitation Twin Cities Animal Rehabilitation and Sports Medicine Clinic), Duncan Lascelles (Professor of Surgery and Pain Management at North Carolina State University College of Veterinary Medicine), Ian G Holsworth (Director VetSurg Small Animal Hospital, Ventura, California), Nick Jeffrey (Professor, Neurology and Neurosurgery College of Veterinary Medicine, Iowa State University), Laurent Findji (Senior Surgeon Soft Tissue and Oncology, Fitzpatrick Referrals) and Jolle Kirpensteijn (Chief Professional Relation Officer, Hill's Pet Nutrition).
And if that wasn't enough, there'll be an evening concert on the Saturday headlined by Mike and the Mechanics. The ONE LIVE concert is being held to promote "One Life One Medicine": the belief that we all only have one life and that there should be a symbiosis of effort to move animal and human medicine forward together. It's in support of The Humanimal Trust, the UK's first charity to further the principles of One Medicine and with the aim of progressing clinically relevant healthcare initiatives for both animals and humans at the same time.
Mike Rutherford said: "I am a huge supporter of 'One Life - One Medicine' - combining animal and human health is an important way forward and I'm looking forward to playing at the Festival, as are the rest of the Mechanics! It will be a fantastic week end - not to be missed!"
As a media partner for the event, VetSurgeon.org will be offering members a special discount, more details to be announced in due course. Publishing Editor Arlo Guthrie said: "Sounds like it should be a lot of fun, and could be a great opportunity for some of our members to meet up and have a pint or two."
All VetSurgeon members can have a 10% discount on the ticket price, by visiting the following link and entering the code VFVSURGEON10
http://www.eventbrite.co.uk/e/the-vet-festival-2015-tickets-16256763417?aff=VFVSURGEON10
For more information about the VET Festival visit: www.vetfestival.co.uk
Running throughout October, the campaign is designed to raise awareness among dog owners of how Adaptil Calm can help dogs cope during the fireworks and Christmas party season.
The advertising campaign will target 3.3 million pet owners and it will air on over 60 channels including C4 channels (Channel 4, E4, More4, Film4, Drama, Good Food, Really, W and Home), Sky channels, ITV2 and ITVBe.
Abigail King, behaviour product manager at Ceva Animal Health, said: "The fireworks and party season can be an extremely upsetting time of the year for the nation’s pets.
"By highlighting the benefits of Adaptil at this key time of the year we hope to ensure that dogs are better prepared for the challenges of fireworks and loud noises."
Ceva says the TV advertising campaign will be supported by a digital campaign for both Adaptil and Feliway.
To watch the Adaptil TV advertisement visit https://www.adaptil.com/uk/Success-Stories/Finley.
RCVS Council agreed, in principle, to the sale of Belgravia House and for the College and its London-based staff to move to different premises at its November meeting.
The sale of the building and the move will be overseen by the College’s Estate Strategy Project Board headed by former RCVS President Barry Johnson and including current and former RCVS Council members and RCVS staff.
The RCVS has been based at its current premises in 62-64 Horseferry Road for 25 years, but says it now needs more up-to-date and modern facilities to accommodate a projected increase in the number of staff.
The College says it has considered a number of alternatives, including expanding the current premises by adding or expanding floors. However, due to the fact that the building is in a conservation area, it has become clear that any such expansions would be unlikely to get planning permission from Westminster Council.
Lizzie Lockett, RCVS Chief Executive, said: "For a number of years it has become apparent that it is fast approaching the time at which our current premises will no longer be fit for purpose due to an increase in the number of RCVS staff – something that is projected to continue in the future – the ongoing need to use the building for Disciplinary Hearings, which take over the lion’s share of available meeting space, and the need for better and more modern facilities.
"Even putting our need for increased space on one side, Belgravia House requires major refurbishment in key areas such as air-conditioning and lifts, which would require staff to vacate the premises for up to 18 months, which would be costly and disruptive.
"We are therefore pleased that Council has recognised the need for the College to move somewhere that better reflects our needs and, over the coming months, we will be exploring a number of different options for new premises.
"In parallel to this we have put out an invitation to tender for agents to manage the sale of the building. The plan is for the arrangement to include lease-back so that we have time to find a suitable premises and enabling us to act quickly when we do."
Any organisations that are interested in putting forward a tender to manage the sale of the building should contact Corrie McCann, RCVS Director of Operations, on 020 7202 0724. Responses to tender are required by 30 November 2018.
Photo: Copyright Google 2018
Otomicol contains miconazole nitrate, prednisolone acetate and polymyxin B.
The product targets a range of pathogens including miconazole and polymyxin B-sensitive, Malassezia and Pseudomonas spp.
Renzo Di Florio, technical vet at Krka UK, said: “With its multifactorial aetiology, ear disease is often challenging to manage, causing frustration for owners and significant discomfort for pets.
"Otomicol is a cost-effective solution that veterinary surgeons can add to their treatment toolbox for cases where bacterial and fungal infection are important factors.”
Otomicol ear drops and cutaneous suspension are available in a 15ml bottle with an extended shelf life of six months after opening.
Otomicol is available from veterinary wholesalers.
https://www.krka.co.uk
The survey, which received 2445 responses from BVA members, found that 16% of vets and vet students have personally experienced discrimination within a veterinary workplace or learning environment in the past twelve months, while 20% had witnessed discrimination.
Senior colleagues were most commonly responsible for the discrimination (47% of incidents), with discrimination from clients accounting for 35% of incidents.
Sex discrimination was the most common type reported (44% of incidents) and was particularly prevalent in academic settings and in production animal, equine, and mixed practices.
Race discrimination was the next most commonly reported (27% of incidents).
Respondents also gave details of discrimination in relation to other protected characteristics, including age, sexuality, disability and gender reassignment.
Younger vets were more likely than older vets to have personally experienced discrimination in the past year (27% of those under 35 had experienced discrimination).
Female vets were more than twice as likely to have experienced discrimination than their male colleagues (19% and 8% respectively).
The incidence of discrimination was higher amongst vets from a range of minority ethnic backgrounds. Those who described their sexual orientation as bi, gay or lesbian were twice as likely to have personally experienced discrimination in the past year.
Despite the high incidence of discrimination reported, responses to the same survey showed that only 56% of the profession feel concerned about discrimination.
British Veterinary Association Junior Vice President Daniella Dos Santos (pictured right) said: "This is the first time anyone has collected such a significant body of evidence on this issue and the results are truly shocking. It is completely unacceptable that so many members of the veterinary team are subject to discrimination not just from clients but from members of our own profession.
"Worryingly, it seems that the scale of the issue will come as a surprise to many members of our profession and so it is vital that we all join the conversation and reflect on what role we can play to improve equality and inclusion. The veterinary team must become a safe and supportive environment for everyone. We cannot accept anything less for ourselves, for our colleagues and for our profession."
Only 12% of respondents were satisfied with how their incident had been dealt, rising to 23% among those who felt able to report. Daniella said: "Many of the experiences documented in our report are shocking and distressing and this distress is often compounded by what comes next. It was very saddening to hear that so many people have felt unable to report their experiences or that their reports were handled badly by those who received them.
"Experiencing discrimination can be very traumatic, without the ‘double-whammy’ of having your complaint dismissed or mishandled by managers or senior staff. We need to make sure everyone who experiences discrimination is able to get the outcome they deserve.
"Through the discrimination questionnaire we heard many distressing stories from vets, students, vet nurses and other colleagues. We are incredibly grateful to them for sharing these with us so that we can raise awareness of what’s happening in our veterinary workplaces."
To raise awareness of the scale of the issue, the BVA is inviting all members of the veterinary team to join a "Big Conversation on equality and inclusion in the veterinary professions", starting with the release of its report on the current situation on discrimination, which can be downloaded here, then inviting everyone to join online engagement sessions through social media and BVA members to feed in views via their regional representatives ahead of Council on 24 July.
Mr Wood faced three charges, all relating to allegations of misconduct over a laboratory test for an alpaca while he was working at a practice in South Oxfordshire.
The charges alleged that in September 2023, Mr Wood told the alpaca’s owner that it had tested positive for Johne’s disease when in fact, the animal had not been tested.
He then allegedly sent a letter confirming a positive test result for the test that had not taken place, and then created a false test result report in the name of a veterinary surgeon colleague and sent it to another colleague by email.
He later told the alpaca's owner that he had given her the wrong result by mistake and that the test result was actually negative.
Then in October 2023, he emailed the laboratory saying that a member of his practice’s administrative staff had written the false report.
In November he told the managing partner of his then employer on three occasions that he was investigating the false report in order to find out who sent it.
Finally, he sent a misleading and dishonest email to a veterinary surgeon colleague falsely indicating that a member of the practice’s staff had manufactured the false report, when that was not the case.
At the outset of the hearing Mr Wood admitted the facts of all the allegations against him.
Having found the facts proven, the Committee found that the charges amounted to serious professional misconduct, something which Mr Wood himself also admitted.
The Committee identified a number of aggravating factors in Mr Woods' conduct, including his lack of honesty, probity and integrity, the fact the conduct was premeditated, that it involved a breach of the client’s trust, the abuse of his professional position, the fact the conduct was sustained and repeated over a period of time, and that his conduct contravened advice given by the RCVS.
The mitigating factors included positive testimonials from professional former colleagues and client farmers, the fact that he had engaged in some remediation in order to avoid repeating the dishonest behaviour, and that he showed significant insight into his misconduct.
Dr Neil Slater MRCVS, chairing the Committee and speaking on its behalf, said: “The Committee recognised that the serious repeated dishonesty, which was to conceal wrongdoing, made the respondent’s misconduct particularly serious.
“It therefore gave consideration as to whether his conduct was fundamentally incompatible with being a veterinary surgeon and whether removal was the only appropriate and proportionate sanction in this case.
“The Committee considered that this was a particularly difficult case to reconcile, as, on the one hand the misconduct was so serious whereas on the other hand, the respondent had demonstrated significant insight; the risk of repetition was low; the evidence of his professional achievements was strong and the testimonials from client farmers and professional colleagues were impressive.”
He added: “The Committee considers that suspension is sufficient in the circumstances of this case to satisfy public confidence in the profession and to uphold proper professional standards of conduct and behaviour.
"The Committee therefore imposes a suspension of 18 months on the respondent.
"In determining this length, the Committee considered that this was the least period necessary in order to meet the significant public interest considerations in this case.”
https://www.rcvs.org.uk/concerns/disciplinary-hearings
According to the survey, 64% of veterinary surgeons now see Brexit as more of a threat than an opportunity for the UK veterinary profession, compared to just half in autumn 2016. Conversely, the number that see Brexit as being more of an opportunity has dropped from 18% to 14% over the same period.
Vets working in academia and industry were the most gloomy: 69% of vets in academia and 58% of vets in industry see Brexit as more of a threat to their own area of work than an opportunity.
The biggest impact appears to have been on veterinary recruitment, with 53% saying Brexit has made it harder to recruit veterinary surgeons, compared to only 18% in 2016. By comparison, only 11% said it has become harder to recruit veterinary nurses.
51% also now consider Brexit as a threat to animal welfare, compared to 43% in 2016.
BVA President Simon Doherty (pictured right, looking decidedly chipper despite it all) said: "As the UK Government ramps up its planning for a no-deal scenario, it’s clear that the veterinary profession is becoming increasingly concerned about the potential impact of Brexit.
"Top of vets’ list of concerns is significant veterinary workforce shortages across critical areas of animal welfare and public health. Veterinary concerns around animal welfare have also increased as the Government continues to stall on introducing new legislation to enshrine animal sentience in UK law before March.
"From pet passports and food safety, to disease surveillance and trade certification, there is no area of veterinary work that is not touched by Brexit. So, we can fully understand why our members are worried about the future. BVA will continue to raise these important veterinary issues with policymakers to ensure the profession is considered as Brexit discussions continue."
The BVA briefings on “Brexit and the veterinary profession” and “No deal Brexit and the veterinary profession” set out all of the issues of interest in more detail.
Clinicians at the Queen Mother Hospital for Animals at the Royal Veterinary College have become the first team in the UK to successfully treat acromegaly in a cat with hypophysectomy surgery.
According to the RVC, this make it the first centre in the UK, and only the fourth in the world, to offer this procedure. The patient groups that might benefit from this RVC-exclusive procedure include cats and dogs with non-functional pituitary tumors, cats and dogs with hyperadrenocorticism (Cushing's disease) and cats with acromegaly or hypersomatotropism.
The RVC says removing the pituitary gland and the associated tumour which causes acromegaly or hyperadrenocorticism is the gold standard treatment in humans suffering from these diseases since it offers the greatest chance of a complete cure for the disease.
Prior to the RVC offering surgical treatment, the only treatment options available for acromegalic cats in the UK were radiation therapy or simply treatment of the resulting diabetes mellitus. The latter can prove extremely difficult and frustrating and the former unpredictable, unreliable and/or ineffective. Even when a complete response to the radiation therapy eventually occurs, hormonal abnormalities usually persist.
Dr Stijn Niessen, leading the hypophysectomy team at the Royal Veterinary College, said: "I'm extremely proud to be able to offer this unique surgery for the first time in the UK at the RVC. As a relatively new and innovative procedure in veterinary medicine there are risks involved, as is recognised with every form of neurosurgery of this level. However, despite these risks, this surgery does offer owners a chance for the best possible result for their pet using a single procedure. Hypophysectomy therefore represents the most elegant treatment method currently available enabling complete removal of the brain tumor and normalisation of damaging excessive hormone levels that are causing hormonal diseases like acromegaly and hyperadrenocorticism.
"Especially when a pituitary tumor is diagnosed late, the alternative treatment method of radiation therapy might well take too long to take effect and devastating neurological signs might occur due to the pressure of the pituitary tumor on the surrounding brain. In such cases, hypophysectomy can make an instant difference in relieving that pressure. However, in general, we would advocate the procedure to be considered as soon as possible following diagnosis, thereby preventing the animal's body from becoming more and more negatively affected by the excessive hormone levels associated with pituitary diseases like acromegaly and hyperadrenocorticism."
Dr. Niessen, a European Veterinary Specialist in Internal Medicine with research interests in diabetes and endocrinology and world-expert in acromegaly, will be selecting the patients suitable for the new treatment, preparing them for surgery and managing the aftercare programme. The longer-term aftercare programme will include hormone replacement treatment administered through eye-drops (usually temporarily) and tablets (permanent) to manage the hormone production lost through removal of the pituitary gland.
The surgery itself will be performed by Patrick Kenny, a European and American Specialist in Veterinary Neurology and Neurosurgery.
The RVC says the surgery would not be possible without the multidisciplinary approach at the Queen Mother Hospital for Animals, which includes the Internal Medicine, Neurology and Neurosurgery, Diagnostic Imaging, Anaesthesia and Emergency and Critical Care teams as well as a team of highly qualified nurses.
To support ongoing research in this field, the Royal Veterinary College is offering free blood tests for all diabetic dogs and cats which include fructosamine evaluation and screening tests for the presence of acromegaly in cats. Cats that record high hormone levels indicative of acromegaly will qualify to undergo a free CT scan for confirmation. If acromegaly is confirmed, all possible treatment options will be discussed with the client, including the hypophysectomy procedure. To request a free blood test for a patient please visit: www.rvc.ac.uk/cic
Veterinary surgeons currently managing a cat or dog with a pituitary tumor who are considering referral of this case can also contact Dr Stijn Niessen for further information at the QMHA on 01707 666365 or at qmhreception@rvc.ac.uk
A survey of almost 1400 ferret owners carried out by the Ferret Education & Research Trust (FERT) and pet food manufacturers James Wellbeloved has revealed that 40% of the UK's ferret owners never take their animals to a vet, with a further 9% saying they visit the vet only occasionally.
In addition, 76% of ferret owners have not had them microchipped, 64% have not bothered with vaccination against distemper and 74% with vaccination against rabies.
Almost three quarters are registered with a vet for emergency treatment, but 26% are not registered at all.
Ian Kearns from FERT said: "This is quite an alarming picture in terms of ferret welfare; however it offers a clear opportunity for vets to address the issue. Ferrets are growing fast in popularity as pets, and it may be that as their role changes they will visit the vet more - but we believe that vets can seize an opportunity by promoting ferret welfare via the waiting room."
The survey also showed that 65% are fed on mixed biscuits and meat. James Wellbeloved Ferret Complete Food was the clear leader, outselling its' nearest rival by almost five times to one. Over half are kept outdoors, and there is a wide choice of bedding material including commercially made washable fabric, straw and paper.
Peter Lancaster, James Wellbeloved marketing director said: "Ferrets are growing in popularity, but because owners sometimes don't do enough research a worrying number are ending up in rescues. Veterinary practices are of course very well-placed to focus on ferret welfare, and we'd urge any vets and vet nurses who want to know more to get in touch with the team at FERT."
10 THINGS YOU NEVER KNEW ABOUT FERRETS...
Carprodyl Quadri is a pork-flavoured, four-way break tablet, available in two presentations of 50mg and 120mg. Each tablet offers four dosage strengths, designed to help you prescribe more accurately for a dog’s weight with fewer boxes on the shelves.
Part tablets can be kept in the blister pack for up to 72 hours, so clients can take home the exact amount of carprofen they require, thereby reducing cost and waste.
To support the launch of Carprodyl Quadri, Ceva is launching a range of marketing materials for veterinary practices. They include: dosage charts, dispensing envelopes, remember to order stickers to stick on boxes left on the shelves, reminder cards about the change for reception and dispensaries and client letters explaining why their prescription has changed.
Lucy Vernon, product manager at Ceva Animal Health said: "Carprodyl Quadri is an easy to administer carprofen that provides accurate dosing while reducing cost and waste and is a welcome addition to our popular pain management portfolio."
For further information, contact your local Ceva Animal Health territory manager.
Vetoquinol is launching Cimalgex, a new NSAID for dogs this month.
Cimalgex (cimicoxib) is a new second generation COX-2 inhibitor which can be used for the treatment of pain and inflammation due to osteoarthritis and the management of peri-operative pain associated with orthopaedic and soft tissue surgery, for which it can be given two hours before surgery and continued for 3-7 days post surgery.
Vetoquinol says that an important consideration in treating dogs with osteoarthritis, many of which are geriatric, is that there are no contraindications to using Cimalgex in patients with mild to moderate renal impairment.
According to the company, field trials showed that over 90 per cent of per owners and vets identified that animals experienced excellent analgesia post operatively*.
Available in a chewable, splitable tablet, Cimalgex can be given with or without food.
Vetoquinol says that the excellent tolerability, efficacy profile and ease of use of Cimalgex means that veterinary patients could benefit from pain relief in situations where clinicians are worried about the risks versus the benefits of prescribing a NSAID for pain management.
Further information about assessing pain and decision making when it comes to prescribing NSAIDs, will be presented in a free webinar on 19th October at 8.30pm. To register go to www.thewebinarvet.com/vetoquinol and enter code CIM1.
Reference*E. Grandemange: Field evaluation of the efficacy and the safety of cimicoxib in the relief of peri-operative pain in dogs; 2008, study number n°3008C2F1
Chanelle has announced the launch of Ketamidor 100 mg/ml Solution for Injection (ketamine), licensed for use in cats, dogs, horses, cattle and swine in the UK and Ireland.
The company says the new product provides a versatile addition to anaesthetic regimes. It can be used in combination with other widely-used anaesthetics and sedatives. Chanelle says it also has analgesic properties that make it particularly beneficial to include in anaesthetic protocols when carrying out painful surgical procedures.
Ketamidor 100mg/ml Solution for Injection has a zero day withdrawal period for milk and meat when used in cattle and pigs, allowing high welfare standards to be maintained without compromising economic returns.
According to Chanelle, ketamine is now experiencing a resurgence of interest as its analgesic properties and minimal impact on spontaneous respiration become increasingly appreciated.1
Angela Wilkin, Chanelle UK's Sales and Marketing Manager said: "Ketamidor makes a great addition to our portfolio of pain management products. Our territory managers are looking forward to speaking to those vets who are already accustomed to using ketamine and those that may be considering adding it to their current protocols."
All practices are eligible to register and no FCA authorisation is needed.
Carefree Credit says it will also process applications to make practice administration hassle free.
Mike Aldred, Director at Carefree Credit, said: "With the deepening cost of living crisis, owning a pet has never been more expensive for many pet owners and having these longer terms available will really help their pets get the treatment they need."
To register your practice with Carefree Credit, email office@carefreecredit.co.uk or call 0345 313 0177.
https://www.carefreecredit.co.uk
Hill's Pet Nutrition has announced that it will not be exhibiting at the British Small Animal Veterinary Association Congress this year, and instead will be found in a restaurant round the corner called The Strada.
The press release containing this news fluttered in at almost exactly same time as one from the BSAVA, in which President Grant Petrie revealed that Congress already has a record-breaking exhibition.
Hill's' spin on the story is that it's all part of a new way of thinking about how the company does business. Blake Hawley, DVM and Managing Director at Hill's Pet Nutrition said: "It's easy to fall into the same old habits and routines. In fact, it can be enormously comforting to predict that in the year ahead, one will deliver, and probably receive, expected results. We don't think that's really quite good enough. So, we made the difficult and very conscious decision to question what we do and challenge how we think about the way we do business."
Hill's goes on to say that it will continue to support BSAVA and help provide a great experience for people attending the Congress, by offering free Italian food, coffee or a glass of beer or wine from its new restaurant location.
Some might call that supportive of BSAVA. Others, less generous, might call it a way of benefitting from all the work that the BSAVA does to bring everyone together at Congress without contributing towards the costs.
Thankfully, though, it doesn't look like BSAVA has been hit that hard by the news. Grant Petrie said: "BSAVA is a not-for-profit registered charity, and Congress is run by vets and nurses. So all of us - organisers, delegates and exhibitors - are supporting the veterinary profession simply by being involved. Together, we are officially part of a record breaking year - with 241 exhibitors in the NIA, along with our fellow associations in the ICC.
"That's more than we've ever had before, and there is a waiting list of companies wanting to join us at this flagship event. So every company who is seriously committed to vets and being involved in supporting the small animal veterinary profession will be with us in the NIA. BSAVA really appreciates the involvement of exhibitors in making Congress such a vital event in the veterinary calendar. It means that not only can we offer remarkably cost-effective CPD, but also provide a showcase of new advances in the industry and the opportunity to get the most from your practice budget. It is where budget holders get the best value, and where exhibitors can meet key decision makers.
"Plus, of course, there's a lot of fun and plenty of free gifts to be found in the NIA too!"
The charges related to the unexpected death of a cat called Hope during an operation to explore a growth in her mouth, and Dr Dantas-Holmes' subsequent communication with the animal's owners.
Dr Dantas-Holmes accepted that Hope’s death was most likely due to her failing to flush fluid through the giving set attached to an intravenous drip, leaving air in the tubing and causing some air to enter Hope’s bloodstream when the cannula was placed and the giving set’s control opened.
The first set of charges related to Dr Dantas-Holmes’ initial phone call to Hope’s owners ten minutes after Hope’s death, in which she said that Hope had died because of a reaction to anaesthetic drugs. Dr Dantas-Holmes failed to mention that the cause of death was still to be determined and failed to mention that a likely cause was in fact an air embolism and/or a complication relating to the intravenous drip.
Following her initial phone call to the owners Dr Dantas-Holmes viewed CCTV of her actions.
The owners then came into the practice later in the day, and the communications during that time constitute the second set of charges: that, during this meeting, Dr Dantas-Holmes didn’t correct her earlier statements about the cause of Hope’s death, and that she didn’t mention that there was an ongoing investigation or that a likely cause of death was an air embolism and/or complication.
The third set of charges related to Dr Dantas-Holmes’ subsequent clinical records, in which it was alleged that she failed to include references to the findings on review of the CCTV footage of Hope’s death, and the possibility of an air embolism and/or complication relating to the intravenous drip.
The fourth and final set of charges were that her conduct was misleading, and/or dishonest.
With regard to the first set of charges, the Committee found that Dr Dantas-Holmes did tell the owners that Hope died because of a reaction to the drugs, but that given the short nature of the phone call to the owners and the distressing circumstances there was no duty to discuss the investigation, or to mention the likely cause being an air embolism.
Concerning the communications with the owners when they came to the practice, the Committee found that Dr Dantas-Holmes did fail to mention that anaesthetic drugs might not have been the cause, and that she also failed to mention the investigation. Dr Dantas-Holmes had agreed with the Practice Manager, however, that she would not discuss the possibility of an air embolism or complication, and so that charge was not found proved.
On consideration of whether Dr Dantas-Holmes had failed to include relevant findings in the clinical reports, the Committee found both charges proved, and, in relation to the final set of charges, the Committee found that while Dr Dantas-Holmes had misled Hope’s owners, it was unintentional, and she had not been dishonest.
Ultimately, the Committee found Dr Dantas Holmes not guilty of disgraceful conduct in a professional respect.
Stuart Drummond, chairing the Committee and speaking on its behalf, said: "The findings of this Committee demonstrate that there were errors and omissions in communications with the owners. When communicating with a client it is the professional’s responsibility to ensure that the client has heard and understood what has been said. The importance of good and effective communication is particularly important when an unforeseen and shocking event occurs such as it did in this case.
"The particular circumstances of this case demonstrate how important it is to communicate effectively and the need for the veterinary surgeon to ensure that their clinical records for which they are wholly responsible, are complete.
"The Committee concluded that its findings demonstrated a departure from professional standards but that the falling short was not so grave as to amount to disgraceful conduct in a professional respect."
The £35 course is aimed at veterinary surgeons, veterinary nurses, receptionists and practice managers who may be faced with difficult and sensitive conversations around pet loss with clients. It covers:
Empathy vs sympathy
Communicating with active listening skills
Open questions
Face-to-face emotional support, telephone support, email support and other written communication
The Blue Cross says that the new course complements its £280, eight-week 'Pet Bereavement Support' course for more in-depth training, and also its hourly webinars, which cost £20.
The eight-week course requires a minimum of three to four hours of study per week and counts towards 32 hours Continual Professional Development.
For specific needs, the Blue Cross can also work with practices to provide bespoke face-to-face training across the UK, specifically tailored and delivered at the practice.
For more information, visit www.bluecross.org.uk/pbss-course or call 01993 867216.
However, many of the causes of above-inflation increases in the cost of veterinary care go well beyond the remit of the CMA and it therefore has limited scope to propose or enforce changes that will likely have any significant impact on costs.
The CMA concluded that the main barriers to healthy competition are: owners not being given enough information, barriers to owners being able to make appropriate choices and an out-of-date regulatory environment.
To correct these issues, the CMA has proposed that veterinary practices should be compelled to:
Given that treatment inflation, rather than a lack of competition, is likely the biggest contributory factor to rising veterinary costs, it seems unlikely that providing price lists, itemised bills or written estimates will do much more than increase the administrative burden on veterinary practices.
What's more, it is very hard to see how price lists and estimates can ever be truly representative in such a complex area as medicine.
So these proposed measures are no more than rearranging deckchairs on the Titanic.
To switch metaphors, the problem is less that pet owners don't know what they're buying and more that the veterinary profession is trying to sell caviar to people who only want or can afford a Big Mac and large fries.
Real change can only be driven by the veterinary profession - not just veterinary surgeons, but the regulator, universities, manufacturers and others, after reflecting on the real, rather than assumed needs of its clients and patients, together with the ethical issues in play.
A good starting point for that reflection is the new book Veterinary Controversies and Ethical Dilemmas, available now: https://www.routledge.com/Veterinary-Controversies-and-Ethical-Dilemmas-Provocative-Reflections-/Clutton-Murphy-Stephens-Taylor/p/book/9781032579863
https://www.gov.uk/guidance/understanding-the-cmas-provisional-decision-in-its-vets-market-investigation